Literature DB >> 9767059

Protease inhibitors as antiviral agents.

A K Patick1, K E Potts.   

Abstract

Currently, there are a number of approved antiviral agents for use in the treatment of viral infections. However, many instances exist in which the use of a second antiviral agent would be beneficial because it would allow the option of either an alternative or a combination therapeutic approach. Accordingly, virus-encoded proteases have emerged as new targets for antiviral intervention. Molecular studies have indicated that viral proteases play a critical role in the life cycle of many viruses by effecting the cleavage of high-molecular-weight viral polyprotein precursors to yield functional products or by catalyzing the processing of the structural proteins necessary for assembly and morphogenesis of virus particles. This review summarizes some of the important general features of virus-encoded proteases and highlights new advances and/or specific challenges that are associated with the research and development of viral protease inhibitors. Specifically, the viral proteases encoded by the herpesvirus, retrovirus, hepatitis C virus, and human rhinovirus families are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9767059      PMCID: PMC88900          DOI: 10.1128/CMR.11.4.614

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  122 in total

Review 1.  HIV protease inhibitors.

Authors:  D L Winslow; M J Otto
Journal:  AIDS       Date:  1995       Impact factor: 4.177

2.  Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group.

Authors:  S L Spruance; A T Pavia; J W Mellors; R Murphy; J Gathe; E Stool; J G Jemsek; P Dellamonica; A Cross; L Dunkle
Journal:  Ann Intern Med       Date:  1997-03-01       Impact factor: 25.391

Review 3.  Structure and assembly of the virion.

Authors:  W Gibson
Journal:  Intervirology       Date:  1996       Impact factor: 1.763

4.  Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

Authors:  D J Kempf; K C Marsh; G Kumar; A D Rodrigues; J F Denissen; E McDonald; M J Kukulka; A Hsu; G R Granneman; P A Baroldi; E Sun; D Pizzuti; J J Plattner; D W Norbeck; J M Leonard
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

5.  Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.

Authors:  C N Hodge; P E Aldrich; L T Bacheler; C H Chang; C J Eyermann; S Garber; M Grubb; D A Jackson; P K Jadhav; B Korant; P Y Lam; M B Maurin; J L Meek; M J Otto; M M Rayner; C Reid; T R Sharpe; L Shum; D L Winslow; S Erickson-Viitanen
Journal:  Chem Biol       Date:  1996-04

6.  The effect of internal autocleavage on kinetic properties of the human cytomegalovirus protease catalytic domain.

Authors:  D R O'Boyle; K Wager-Smith; J T Stevens; S P Weinheimer
Journal:  J Biol Chem       Date:  1995-03-03       Impact factor: 5.157

7.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.

Authors:  J H Condra; W A Schleif; O M Blahy; L J Gabryelski; D J Graham; J C Quintero; A Rhodes; H L Robbins; E Roth; M Shivaprakash
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

8.  In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.

Authors:  H Jacobsen; M Hänggi; M Ott; I B Duncan; S Owen; M Andreoni; S Vella; J Mous
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

9.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

Authors:  A C Collier; R W Coombs; D A Schoenfeld; R L Bassett; J Timpone; A Baruch; M Jones; K Facey; C Whitacre; V J McAuliffe; H M Friedman; T C Merigan; R C Reichman; C Hooper; L Corey
Journal:  N Engl J Med       Date:  1996-04-18       Impact factor: 91.245

10.  Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.

Authors:  P S Dragovich; S E Webber; R E Babine; S A Fuhrman; A K Patick; D A Matthews; C A Lee; S H Reich; T J Prins; J T Marakovits; E S Littlefield; R Zhou; J Tikhe; C E Ford; M B Wallace; J W Meador; R A Ferre; E L Brown; S L Binford; J E Harr; D M DeLisle; S T Worland
Journal:  J Med Chem       Date:  1998-07-16       Impact factor: 7.446

View more
  54 in total

1.  Viral capsid mobility: a dynamic conduit for inactivation.

Authors:  K Broo; J Wei; D Marshall; F Brown; T J Smith; J E Johnson; A Schneemann; G Siuzdak
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

2.  Use of fluorescence resonance energy transfer for rapid detection of enteroviral infection in vivo.

Authors:  Yu-Chen Hwang; Wilfred Chen; Marylynn V Yates
Journal:  Appl Environ Microbiol       Date:  2006-05       Impact factor: 4.792

3.  Outliers in SAR and QSAR: is unusual binding mode a possible source of outliers?

Authors:  Ki Hwan Kim
Journal:  J Comput Aided Mol Des       Date:  2007-03-03       Impact factor: 3.686

4.  High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.

Authors:  Matthew J Saunders; Steven W Graves; Larry A Sklar; Tudor I Oprea; Bruce S Edwards
Journal:  Assay Drug Dev Technol       Date:  2010-02       Impact factor: 1.738

5.  Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.

Authors:  Prasenjit Mukherjee; Falgun Shah; Prashant Desai; Mitchell Avery
Journal:  J Chem Inf Model       Date:  2011-05-23       Impact factor: 4.956

6.  HEPT derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase: QSAR studies agree with the crystal structures.

Authors:  Anderson Coser Gaudio; Carlos Alberto Montanari
Journal:  J Comput Aided Mol Des       Date:  2002-04       Impact factor: 3.686

7.  Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor.

Authors:  L S Zalman; M A Brothers; P S Dragovich; R Zhou; T J Prins; S T Worland; A K Patick
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

8.  Provirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.

Authors:  Jie Lan; Kai Yang; Daniel Byrd; Ningjie Hu; Tohti Amet; Nicole Shepherd; Mona Desai; Jimin Gao; Samir Gupta; Yongtao Sun; Qigui Yu
Journal:  J Immunol       Date:  2014-08-22       Impact factor: 5.422

9.  In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease.

Authors:  A K Patick; S L Binford; M A Brothers; R L Jackson; C E Ford; M D Diem; F Maldonado; P S Dragovich; R Zhou; T J Prins; S A Fuhrman; J W Meador; L S Zalman; D A Matthews; S T Worland
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

10.  First generation inhibitors of the adenovirus proteinase.

Authors:  William J McGrath; Vito Graziano; Katarzyna Zabrocka; Walter F Mangel
Journal:  FEBS Lett       Date:  2013-05-24       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.